Characterizing CDK12-Mutated Prostate Cancers.

Pasquale RescignoBora GurelRita PereiraMateus CrespoJan Rekowski Mattia ReditiMaialen BarreroJoaquin MateoDiletta BianchiniCarlo MessinaMaria D Fenor de la MazaKhobe ChandranJuliet CarmichaelChristina GuoAlec PaschalisAdam SharpGeorge SeedInes FigueiredoMaryou LambrosSusana MirandaAna FerreiraClaudia BertanRuth RiisnaesNuria PortaWei YuanSuzanne CarreiraJohann S de Bono

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

CDK12-altered mCRPCs have worse prognosis, with these tumors surprisingly being primarily enriched for CD4+FOXP3- cells that seem to associate with worse outcome and may be immunosuppressive.See related commentary by Lotan and Antonarakis, p. 380.

Keyphrases

cell cycle
induced apoptosis
prostate cancer
cell cycle arrest
regulatory t cells
benign prostatic hyperplasia
cell proliferation
immune response
nk cells
dendritic cells